Acquired by Leica in June 2015, Bioptigen - spun out of Duje University - in the field of optical coherence tomography (OCT), an imaging technique using light to capture extremely high-resolution, three-dimensional pictures of the eye. The firm's in vivo optical imaging platform is used to diagnose macular degeneration and glaucoma. The technology supports real-time, noninvasive imaging of internal tissue microstructure. Systems also can be used in drug development, genetics research, tissue engineering and medical vision, The firm offers Bioptigen Envisu C-Class SDOIS : ophthalmic optical coherence tomography imaging systems for hand-held imaging of patients from premature infant to adult; spectral domain ophthalmic imaging systems for pre-clinical and non-clinical research; and systems for ultra-high resolution imaging over limited imaging depths and high resolution imaging over broader imaging depths. The company also provides InVivoVue Clinic, a database-driven program for patient follow-up and management; and training and support services. Products are offered to ophthalmic research institutions, and ophthalmic equipment and pharmaceutical companies in support of pre-clinical research and development. Bioptigen Inc. is an ISO 13485-certified medical device company that develops innovative ophthalmic imaging solutions. Bioptigens Envisu(tm) R-class systems are ideally suited to non-invasive ophthalmic imaging of animals ranging from zebrafish to elephants. Using low-power, near-infrared light, Envisu generates real-time, high-resolution, volumetric images of ocular microstructures from the cornea to the retina. Bioptigen has received CE approval to market its hand-held Envisu R2000 systems for preclinical use and C2000 systems for clinical use within the EU.
